Remicade: Warnings Added to Drug Label

Important safety information has been added by Centocor (the maker of Remicade) and the U.S. Food and Drug Administration to the label of the rheumatoid arthritis drug. Based on worldwide postmarketing experience the following hematologic events, sometimes fatal, were reported in patients receiving Remicade: leukopenia, neutropenia, thromobcytopenia, and pancytopenia. The warning on neurologic events has been updated too. How many people have been affected? Should you be worried if you take an anti-TNF drug? Read about the new warnings.